J&J Takes The Lead In Settling SEC/DoJ Foreign Corrupt Practices Act Probe
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson agreed to pay $70 million to resolve charges by the Securities and Exchange Commission and the Department of Justice that the company bribed doctors in several European countries to order or prescribe its products in violation of the Foreign Corrupt Practices Act